MISC

2007年7月

Midkine as a novel target for antibody therapy in osteosarcoma

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
  • Hiroki Maehara
  • Tadashi Kaname
  • Kumiko Yanagi
  • Hiroaki Hanzawa
  • Ichiro Owan
  • Takao Kinjou
  • Kenji Kadomatsu
  • Shinya Ikematsu
  • Teruo Iwamasa
  • Fuminori Kanaya
  • Kenji Naritomi
  • 全て表示

358
3
開始ページ
757
終了ページ
762
記述言語
英語
掲載種別
DOI
10.1016/j.bbrc.2007.04.183
出版者・発行元
ACADEMIC PRESS INC ELSEVIER SCIENCE

Osteosarcoma is a malignant tumor with poor prognosis, and lack of accurate prognostic factors is one of the reasons that make this tumor difficult to cure. The heparin-binding growth factor, midkine is involved in generation and progression of many types of tumors. However, the relationship between midkine and osteosarcoma has been unclear. We show here that midkine is overexpressed in osteosarcoma and the level of midkine expression is correlated with prognosis (P < 0.05; log-rank test). Treatment with functional antibodies against midkine suppresses growth of osteosarcoma cell lines, 9N2, 3N1, Saos-2, and NOS-1, to 25-65% of untreated controls. Our results suggest that midkine is useful as a prognostic marker, and is a candidate therapeutic target for osetosarcomas. (c) 2007 Elsevier Inc. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.bbrc.2007.04.183
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000247124900015&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.bbrc.2007.04.183
  • ISSN : 0006-291X
  • Web of Science ID : WOS:000247124900015

エクスポート
BibTeX RIS